In this review, we explore ovarian cancer specific factors with links to aberrant activity of Nrf2, to be exploited in future combination strategies, synergistic with direct Nrf2 inhibitory drugs.
Patient-selection strategies, different schedules and other demethylating agents should be considered in future combination studies.
Given its excellent safety profile and distinct mechanism of action from most other chemotherapeutics, it may be a candidate for inclusion in future combination approaches.
The integration of CSC-targeted therapies and immune therapies in future combination regimens holds promise in addressing this unexplored area of clinical research and likely curing a larger proportion of women with metastatic BC.
Finally, the integration of cancer stem cell-targeted therapies and immune therapies in future combination regimens increases our chances to successfully treat a larger proportion of women with more aggressive and resistant metastatic disease.
In the future, combinations of gene variants might be analyzed by "omics" approach, where bioinformatics integrate genomics, epigenomics, transcriptomics, proteomics and metabolomics [73, 74].
In the future, combinations of targeted agents with radiotherapy could prove to be an area of impactful investigation as there may be complementary targeted agents that enhance tumor kill without significantly increasing toxicity.
Finally, a large number of treatments based on the modulation of immunotherapy are being developed (Melero et al, 2007) and some of them are being tested in patients with metastatic RCC, suggesting that, in the near future, combinations of targeted agents with new immunotherapeutic approaches might become a reality (Coppin et al, 2008).
In the near future combinations of antiviral agents with no cross resistance and improved safety profile will further reduce treatment durations and will become the new recommended HCV regimens making HCV the first viral infection to be possibly eradicated worldwide.
This approach works best if you have several future combinations in mind, and can see how the board will look a few moves ahead.
